Payment overview · 2025
General Payments
$13.93
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael V Zelman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA MONICA, CA · NPI 1790732964
Verified facts
What the public records show
CMS Open Payments records show Michael V Zelman, M.D. received $13.93 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.93 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.93 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 87 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
139 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 666 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 637 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 35 |
| Metformin Hcl | Metformin Hcl | 346 | 37 |
| Losartan Potassium | Losartan Potassium | 294 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 30 |
| Eliquis | Apixaban | 218 | 27 |
| Ezetimibe | Ezetimibe | 193 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 22 |
| Chlorthalidone | Chlorthalidone | 188 | 27 |
| Dexlansoprazole Dr | Dexlansoprazole | 187 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 186 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 24 |
| Clonazepam | Clonazepam | 154 | 19 |
| Donepezil Hcl | Donepezil Hcl | 148 | 18 |
| Lorazepam | Lorazepam | 148 | 21 |
| Allopurinol | Allopurinol | 140 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 25 |
| Synthroid | Levothyroxine Sodium | 139 | 14 |
| Famotidine | Famotidine | 136 | 19 |
| Omeprazole | Omeprazole | 123 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 120 | 13 |
| Celecoxib | Celecoxib | 117 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 17 |
| Furosemide | Furosemide | 109 | 17 |
| Atenolol | Atenolol | 106 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 103 | 12 |
| Nitroglycerin | Nitroglycerin | 101 | 12 |
| Montelukast Sodium | Montelukast Sodium | 93 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | suppressed |
| Creon | Lipase/Protease/Amylase | 87 | 17 |
| Jardiance | Empagliflozin | 86 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 83 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 82 | 12 |
| Linzess | Linaclotide | 82 | 13 |
| Lidocaine | Lidocaine | 81 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 77 | suppressed |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Irbesartan | Irbesartan | 76 | suppressed |
| Carvedilol | Carvedilol | 73 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 71 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 14 |
| Farxiga | Dapagliflozin Propanediol | 68 | suppressed |
| Valsartan | Valsartan | 65 | 11 |
| Gabapentin | Gabapentin | 63 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | suppressed |
| Lisinopril | Lisinopril | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Dutasteride | Dutasteride | 49 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Edarbi | Azilsartan Medoxomil | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 39 | suppressed |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 34 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Captopril | Captopril | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Ramelteon | Ramelteon | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Horizant | Gabapentin Enacarbil | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Diovan | Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.93 · 1 records | ABBVIE INC. | CREON, LINZESS | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error